gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Thymidine phosphorylase

thymidine phosphorylase, PD-ECGF
This gene encodes an angiogenic factor which promotes angiogenesis in vivo and stimulates the in vitro growth of a variety of endothelial cells. It has a highly restricted target cell specificity acting only on endothelial cells. Mutations in this gene have been associated with mitochondrial neurogastrointestinal encephalomyopathy. Multiple alternatively spliced variants, encoding the same protein, have been identified. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HAD, CAN, vascular endothelial growth factor, POLYMERASE, AGE
Papers on thymidine phosphorylase
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Beumer et al., Pittsburgh, United States. In Cancer Chemother Pharmacol, Feb 2016
FTD is a thymidine analog, and it is degraded by thymidine phosphorylase (TP) to the inactive trifluoromethyluracil (FTY) metabolite.
TAS-102 an Emerging Oral Fluoropyrimidine.
Saif et al., Australia. In Anticancer Res, Jan 2016
Various approaches have been used to improve the efficacy of 5-FU including inhibition of its degradation enzyme dihydropyrimidine dehydrogenase (DPD) such as S1, UTF, use of 5-FU pro-drug capecitabine to exploit thymidine phosphorylase (TP) and supplementation of reduced folate acid to increase cytotoxicity.
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Di Gennaro et al., Napoli, Italy. In Oncotarget, Jan 2016
Capecitabine, which is commonly used for metastatic breast cancer in different settings, is an inactive prodrug that takes advantage of elevated levels of thymidine phosphorylase (TP), a key enzyme that is required for its conversion to 5-fluororacil, in tumors.
Kinetics and mechanistic study of competitive inhibition of thymidine phosphorylase by 5-fluoruracil derivatives.
Mancini et al., L'Aquila, Italy. In Colloids Surf B Biointerfaces, Jan 2016
The experimental investigation was supported by docking simulations based on the X-ray structure of thymidine phosphorylase (TP) from Escherichia coli complexed with 3'-azido-2'-fluoro-dideoxyuridin.
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.
Peters, Amsterdam, Netherlands. In Ther Adv Med Oncol, Nov 2015
TAS-102, a combination of trifluorothymidine and the thymidine phosphorylase inhibitor TPI in a 1:0.5 ratio, is a novel oral formulation, which is active in 5FU-resistant models, both in vitro and in xenograft models.
TAS-102 for the treatment of metastatic colorectal cancer.
Masi et al., Pisa, Italy. In Expert Rev Anticancer Ther, Nov 2015
TAS-102 is an orally administered combination of the nucleoside analogue trifluridine and tipiracil hydrochloride, a thymidine phosphorylase inhibitor.
TAS-102, a novel antitumor agent: A review of the mechanism of action.
Loupakis et al., Los Angeles, United States. In Cancer Treat Rev, Nov 2015
TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD.
Thymidine Phosphorylase in Cancer; Enemy or Friend?
Gately et al., Dublin, Ireland. In Cancer Microenviron, Sep 2015
UNASSIGNED: Thymidine phosphorylase (TP) is a nucleoside metabolism enzyme that plays an important role in the pyrimidine pathway.TP catalyzes the conversion of thymidine to thymine and 2-deoxy-α-D-ribose-1-phosphate (dRib-1-P).
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Xi et al., Taiyuan, China. In Int J Clin Exp Pathol, 2014
Of these enzymes, thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD) are known to play important roles in the efficacy of therapeutic agents.
Orotate phosphoribosyltransferase localizes to the Golgi complex and its expression levels affect the sensitivity to anti-cancer drug 5-fluorouracil.
Goto et al., Yamagata, Japan. In Biomed Res, 2014
Furthermore, chemotherapeutic drug 5-fluorouracil (5-FU) is taken up into cancer cells and is converted to 5-fluoro-UMP (FUMP) by OPRT or to 5-fluoro-dUMP (FdUMP) through intermediary molecules by thymidine phosphorylase.
Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells.
Akiyama et al., Tokushima, Japan. In Oncol Rep, 2012
The enzymatic activity of thymidine phosphorylase was required for the enhanced expression of IL-8 in human cancer cells.
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Uchida et al., Japan. In Cancer Chemother Pharmacol, 2012
TP gene expression levels in primary CRC tissues and the primary tumor site may be useful predictors of the efficacy of oral UFT/LV chemotherapy.
Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma.
Yi et al., Jingzhou, China. In Eur J Surg Oncol, 2012
High TP/PD-ECGF expression and thrombocytosis can be regarded as valuable tools for predicting overall survival in patients with gastric carcinoma.
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Cardenes et al., Indianapolis, United States. In Cancer Chemother Pharmacol, 2012
Data indicate that high thymidine phosphorylase (TP) tumor gene expression was associated with obtaining pathological complete response (pCR).
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Hibi et al., Yokohama, Japan. In Anticancer Res, 2012
mRNA expression of TYMS, DPYD, and TYMP is associated with distinct characteristics and may be useful for predicting survival in patients with stage IV colorectal cancer.
Archaeal type III RuBisCOs function in a pathway for AMP metabolism.
Imanaka et al., Kyoto, Japan. In Science, 2007
Genes annotated as thymidine phosphorylase (deoA) and eucaryal translation initiation factor 2B (e2b2) were found to encode AMP phosphorylase and ribose-1,5-bisphosphate isomerase, respectively.
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
ASCO et al., Alexandria, United States. In J Clin Oncol, 2006
Data are insufficient to recommend the routine use of p53, ras, thymidine synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, microsatellite instability, 18q loss of heterozygosity, or deleted in colon cancer (DCC) protein in the management of patients with colorectal cancer.
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Schwarting et al., Philadelphia, United States. In J Clin Oncol, 2006
PURPOSE: To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity.
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Jakob et al., Göttingen, Germany. In J Clin Oncol, 2006
Furthermore, the prognostic value of molecular biomarkers, such as thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD), all of which are involved in the FU metabolism, is unknown in neoadjuvant settings.
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Johnson et al., Birmingham, United States. In J Clin Oncol, 2006
PURPOSE: To establish the feasibility of capecitabine with concurrent radiotherapy (XRT) in patients with locally advanced (LA) pancreatic cancer and evaluate the effect of XRT on thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and tumor necrosis factor-alpha (TNF-alpha).
share on facebooktweetadd +1mail to friends